Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium

Lonza has launched the TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium to expand its GMP solutions for cell and gene therapy. The products provide researchers and manufacturers with high-performance, scalable and regulatory-ready solutions that help streamline cell and gene therapy workflows from discovery through clinical development.

Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. TheraPEAK AmpliCell Cytokines enable the expansion, activation and differentiation of immune cells, for an easy transition from research to manufacturing.

Produced in a mammalian expression system and engineered for high biological activity, the cytokines feature proper folding and glycosylation, delivering native-like structure and function that bacterial systems cannot match, according to the company. This enables good biological relevance, batch-to-batch consistency, and predictability in sensitive and translational applications, both in research and GMP set-ups.

TheraPEAK 293-GT Medium is a chemically defined, animal-origin-free system optimised for adeno-associated virus (AAV) production in suspension HEK293 cells, providing a scalable option for advancing gene therapy programs. Unlike off-the-shelf viral production kits that may lack flexibility, the 293-GT System (growth medium plus supplement) is a drop-in-ready solution engineered to integrate seamlessly with existing workflows.

The product is compatible with commercially available transfection reagents and AAV enhancers, delivers strong AAV titres, and supports high full-to-empty capsid ratios. It is designed to accelerate development timelines and improve consistency from research through to GMP gene therapy production.